Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allakos Inc.

www.allakos.com

Latest From Allakos Inc.

Novartis Targets Chronic Urticaria As Ligelizumab Enters Late-Stage Trials

Two Phase III studies, PEARL 1 and PEARL 2, will compare Novartis's candidate anti-IgE antibody with the previous generation anti-IgE MAb, Xolair, for the treatment of chronic spontaneous urticaria.

 

Dermatology Clinical Trials

Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year

Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.

Financing Business Strategies

Finance Watch: 2018 Biopharma VC Investment Could Beat 2017 One Quarter Ahead Of Schedule

With biopharma venture capital investment of $9.67bn during the first half, 2018's total is on track to beat 2017 in the third quarter. IPOs, one of the factors fueling VC investment, continue to boom with five more drug developers slated to go public this week.

Financing Business Strategies

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment

Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gastrointestinal
  • Immune Disorders
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allakos Inc.
  • Senior Management
  • Robert Alexander, PhD, CEO
    Adam Tomasi, PhD, COO & CFO
    Henrik Rasmussen, MD, PhD, CMO
    Simon Greenwood, PhD, CBO
  • Contact Info
  • Allakos Inc.
    Phone: (650) 597-5002
    75 Shoreway Rd.
    Ste. A
    San Carlos, CA 94070
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register